Central Nervous System Therapeutics Market To Reach $273.32 Billion By 2033

Central Nervous System Therapeutics Market Growth & Trends

The global central nervous system therapeutics market size is expected to reach USD 273.32 billion by 2033, registering a CAGR of 9.1% from 2026 to 2033, according to a new report by Grand View Research, Inc. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo’s zinc finger platform to develop therapies for Alzheimer’s disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

 Request a free sample copy or view report summary: Central Nervous System Therapeutic Market Report

Central Nervous System Therapeutics Market Report Highlights

• The mental health segment dominated the market with the largest revenue share of 34.13% in 2025, driven by the rising prevalence of disorders such as depression, anxiety, bipolar disorder, and schizophrenia across all age groups.

• The antidepressants segment dominated the market with the largest revenue share of 24.77% in 2025 due to the high prevalence of depression and anxiety disorders worldwide.

• The hospital pharmacy segment dominated the market with the largest revenue share of 46.46% in 2025, due to the high volume of patients receiving treatment for complex neurological and psychiatric conditions in hospital settings.

• North America held the largest central nervous system therapeutics market share of 41.80% in 2025, driven by high prevalence of neurological and psychiatric disorders across the region.

Central Nervous System Therapeutics Market Segmentation

Grand View Research has segmented the central nervous system therapeutics market on the basis of disease, drug class, distribution channel, region:

Central Nervous System Therapeutics Disease Outlook (Revenue, USD Million, 2021 - 2033)

• Neurovascular Diseases

• CNS Trauma

• Mental Health

  • Anxiety Disorders

  • Epilepsy

  • Mood Disorders

  • Psychotic Disorders

  • Others

• Neurodegenerative Diseases

  • Alzheimer’s Disease

  • Parkinsosn’s Disease     

  • Multiple Sclerosis

  • Huntington’s Disease

  • Amytrophic Lateral Sclerosis

  • Others

• Infectious Diseases

• CNS Cancer

• Others

Central Nervous System Therapeutics Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

• Antidepressants

• Antipsychotics

• Antiepileptics (AEDs)

• Dopaminergic Agents

• Neuroprotective Agents

• Immunomodulators

• Others

Central Nervous System Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Pharmacy

• Retail Pharmacy

• Others

Central Nervous System Therapeutics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Central Nervous System Therapeutics Market

• Biogen

• Otsuka Pharmaceutical Co., Ltd.

• Eli Lilly and Company

• Merck & Co., Inc.

• AstraZeneca

• Takeda Pharmaceutical Company Limited.

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Johnson & Johnson Services, Inc.

• Pfizer, Inc.